000127545 001__ 127545
000127545 005__ 20240228140935.0
000127545 0247_ $$2doi$$a10.18632/oncotarget.3927
000127545 0247_ $$2pmid$$apmid:25970789
000127545 0247_ $$2pmc$$apmc:PMC4546489
000127545 0247_ $$2altmetric$$aaltmetric:4015265
000127545 037__ $$aDKFZ-2017-03568
000127545 041__ $$aeng
000127545 082__ $$a610
000127545 1001_ $$aStaal, Jerome A$$b0
000127545 245__ $$aProteomic profiling of high risk medulloblastoma reveals functional biology.
000127545 260__ $$a[S.l.]$$bImpact Journals LLC$$c2015
000127545 3367_ $$2DRIVER$$aarticle
000127545 3367_ $$2DataCite$$aOutput Types/Journal article
000127545 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1508852661_20352
000127545 3367_ $$2BibTeX$$aARTICLE
000127545 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127545 3367_ $$00$$2EndNote$$aJournal Article
000127545 520__ $$aGenomic characterization of medulloblastoma has improved molecular risk classification but struggles to define functional biological processes, particularly for the most aggressive subgroups. We present here a novel proteomic approach to this problem using a reference library of stable isotope labeled medulloblastoma-specific proteins as a spike-in standard for accurate quantification of the tumor proteome. Utilizing high-resolution mass spectrometry, we quantified the tumor proteome of group 3 medulloblastoma cells and demonstrate that high-risk MYC amplified tumors can be segregated based on protein expression patterns. We cross-validated the differentially expressed protein candidates using an independent transcriptomic data set and further confirmed them in a separate cohort of medulloblastoma tissue samples to identify the most robust proteogenomic differences. Interestingly, highly expressed proteins associated with MYC-amplified tumors were significantly related to glycolytic metabolic pathways via alternative splicing of pyruvate kinase (PKM) by heterogeneous ribonucleoproteins (HNRNPs). Furthermore, when maintained under hypoxic conditions, these MYC-amplified tumors demonstrated increased viability compared to non-amplified tumors within the same subgroup. Taken together, these findings highlight the power of proteomics as an integrative platform to help prioritize genetic and molecular drivers of cancer biology and behavior.
000127545 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000127545 588__ $$aDataset connected to CrossRef, PubMed,
000127545 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000127545 7001_ $$aLau, Ling San$$b1
000127545 7001_ $$aZhang, Huizhen$$b2
000127545 7001_ $$aIngram, Wendy J$$b3
000127545 7001_ $$aHallahan, Andrew R$$b4
000127545 7001_ $$0P:(DE-HGF)0$$aNorthcott, Paul A$$b5
000127545 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b6$$udkfz
000127545 7001_ $$aWechsler-Reya, Robert J$$b7
000127545 7001_ $$aRusert, Jessica M$$b8
000127545 7001_ $$aTaylor, Michael D$$b9
000127545 7001_ $$aCho, Yoon-Jae$$b10
000127545 7001_ $$aPacker, Roger J$$b11
000127545 7001_ $$aBrown, Kristy J$$b12
000127545 7001_ $$aRood, Brian R$$b13
000127545 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.3927$$gVol. 6, no. 16, p. 14584 - 14595$$n16$$p14584 - 14595$$tOncoTarget$$v6$$x1949-2553$$y2015
000127545 909CO $$ooai:inrepo02.dkfz.de:127545$$pVDB
000127545 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000127545 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000127545 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000127545 9141_ $$y2015
000127545 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000127545 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127545 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127545 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127545 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127545 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127545 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127545 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127545 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000127545 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000127545 980__ $$ajournal
000127545 980__ $$aVDB
000127545 980__ $$aI:(DE-He78)B062-20160331
000127545 980__ $$aUNRESTRICTED